Definium Therapeutics (DFTX) jumps in premarket on Phase 3 depression trial

Definium Therapeutics Inc. surged in pre-market trading after the company said its LSD-based DT120 tablet hit the main target in a late-stage depression trial. The New York biotech traded at $40.19 on Public.com at 9:00 a.m. ET, up 64.2% from Friday’s close of $24.48. Nasdaq’s session hadn’t started yet, with the open set for 9:30 a.m. ET.

NASDAQ:CMPS · NASDAQ:DFTX · Stock Market
Follow on Google News
Add as preferred source Open in Google News

US Stock Market Today Updates

AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 Strong buy

Alphabet

NASDAQ:GOOGL 92/100 • ★★★★½
#2 Strong buy

Taiwan Semiconductor Manufacturing

NYSE:TSM 89/100 • ★★★★½
#3 Buy

S&P Global

NYSE:SPGI 88/100 • ★★★★
#4 Buy on weakness

Amazon

NASDAQ:AMZN 86/100 • ★★★★
#5 Buy on weakness

Microsoft

NASDAQ:MSFT 84/100 • ★★★★
View full portfolio
Editorial model selection. Not personalised advice.
MARKET CALENDAR

Key Events Today

The catalysts most likely to move markets.

#1

Chicago Fed National Activity Index

A surprise around the 0.10 forecast could shift the morning growth narrative and influence Treasury yields and the dollar before the opening bell.

#2

PDD Holdings earnings

The day’s largest scheduled equity report can move PDD and the broader China-internet / e-commerce complex through revenue growth, margins and Temu commentary.

#3

XPeng earnings

Deliveries, margin progression and spending on AI-enabled mobility can affect U.S.-traded Chinese EV names and related technology suppliers.

View full calendar
Times and estimates may change. Verify before trading.